RxDoctor Payments DataLook up a doctor →

Gavin Brown, MD

Neurology · Canton, GANPI 1710164975

Payments from drug & device makers

$86,205in general payments, 2019–2025

Across 352 payments — averaging $244.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$54K
  • UCB, Inc.$11K
  • Argenx US, Inc.$9K
  • Lilly USA, LLC$5K
  • Johnson & Johnson$2K
  • AbbVie$1K
  • plus $5K from 48 others

What the payments were for

  • Consulting fees$23,92036%
  • Speaking & faculty fees$34,81352%
  • Travel & lodging$6991%
  • Food & beverage$7,23811%
  • Education$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,205 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$186,617
Medicare patients
627
Services billed
2,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab32$1,154,571
VyvgartEfgartigimod Alfa-Fcab16$1,117,968
Gamunex-CImmune Globul G/Gly/Iga Avg 4671$760,292
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5026$667,272
RystiggoRozanolixizumab-Noli14$656,014
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5045$647,294
GammakedImmune Globul G/Gly/Iga Avg 4626$249,704
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5034$238,806
CopaxoneGlatiramer Acetate28$161,892
RytaryCarbidopa/Levodopa69$95,993
VimpatLacosamide17$53,697
UbrelvyUbrogepant40$52,115
GocovriAmantadine Hcl13$46,150
Aimovig AutoinjectorErenumab-Aooe48$33,650
KeppraLevetiracetam31$29,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$53,517$1,154,57132 claims
Argenx US, Inc.Vyvgart$8,513$1,117,96816 claims
Grifols USA, LLCGamunex-C$58$760,29271 claims
UCB, Inc.Rystiggo, Vimpat$10,762$709,71131 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$35$647,29445 claims
CSL BehringPrivigen$65$238,80634 claims
Teva Pharmaceuticals USA, Inc.Copaxone$93$161,89228 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$98$111,222204 claims
AbbVieUbrelvy$1,126$52,11540 claims
MDD US Operations, LLCGocovri$546$46,15013 claims
PfizerNurtec Odt$471$21,66415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →